Endometriosis is a gynecologic disorder affecting 6–10% of reproductive-aged women. First-line therapies are progestin-based regimens; however, failure rates are high, often requiring alternative hormonal agents, each with unfavorable side effects. Bazedoxifene with conjugated estrogens is approved for treatment of menopausal symptoms, and use in animal studies has demonstrated regression of endometriotic lesions. As such, it represents a potential treatment option for endometriosis.
A patient with stage III endometriosis referred for management of dysmenorrhea and cyclic pelvic pain was treated with 20 mg bazedoxifene and 0.45 mg conjugated estrogens daily for more than 6 months. She noted resolution of pelvic pain. There were no abnormal effects on hormonal, uterine, or ovarian parameters.
Bazedoxifene with conjugated estrogens may be an effective alternative to traditional endometriosis treatment options.
Bazedoxifene with conjugated estrogens may represent a new therapeutic option for management of endometriosis-associated pain.
Department of Obstetrics, Gynecology, and Reproductive Sciences and the John B. Pierce Laboratory, Yale School of Medicine, New Haven, Connecticut.
Corresponding author: Valerie A. Flores, MD, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06510; email: email@example.com.
Financial Disclosure The authors did not report any potential conflicts of interest.
The authors thank Cheryl Leone, MS, for her assistance in blood sample collection and data analysis.
Each author has indicated that he or she has met the journal's requirements for authorship.
Received March 31, 2018. Received in revised form May 9, 2018. Accepted May 17, 2018.
Received March 31, 2018
Received in revised form May 09, 2018
Accepted May 17, 2018